Atogepant versus topiramate trial (TEMPLE) evaluated tolerability, safety, and efficacy in migraine prevention.
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.
Abstract
The TEMPLE trial, a phase 3b study, aimed to compare atogepant 60 mg daily against topiramate for tolerability, safety, and efficacy in adults with migraine.